GlobeNewswire Inc | Jul 16, 2021 04:01PM EDT

July 16, 2021

HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 6,845,238 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 892,857 shares, at a public offering price of $42.00 per share. The gross proceeds to Celldex from this offering were approximately $287.5 million, before deducting underwriting discounts and commissions and offering expenses.

Jefferies, SVB Leerink, Guggenheim Securities and Cantor acted as joint book-running managers for the offering. LifeSci Capital LLCand H.C. Wainwright & Co. acted as co-lead managers for the offering.

The securities described above were offered and sold by Celldex pursuant to a prospectus supplement and an accompanying base prospectus forming part of a shelf registration statement on Form S-3 (File No. 333-249917), which was deemed effective by the Securities and Exchange Commission (SEC) on November 6, 2020, and are available on the SECs website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus may be obtained for free by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by e-mail at prospectus_department@jefferies.com; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by e-mail at syndicate@svbleerink.com; or Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at prospectus@cantor.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Forward Looking Statement

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as believes, expects, anticipates, intends, will, may, should, or similar expressions. These forward-looking statements reflect managements current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Companys business in general, please refer to the Companys prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Companys Form 10-K for the year ended December 31, 2020 and Form 10-Q for the quarter ended March 31, 2021.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & AdministrationCelldex Therapeutics, Inc.(508) 864-8337scavanaugh@celldex.com

Patrick TillSenior Director, Investor Relations & Corporate CommunicationsCelldex Therapeutics, Inc.(484) 788-8560ptill@celldex.com